TABLE 7.

Clinical trials of intensive-phase intravenous antibiotics in severe melioidosis

ReferenceRegimen (dose, mg/kg/day)Duration (days)No. of patientsOutcome measures (%)
EnrolledCulture confirmedTreatment failureMortality
473 Ceftazidime (120) vs chloramphenicol (100), doxycycline (4), and TMP-SMX (10/50)At least 716134 vs 3137 vs 74
400 Ceftazidime (100) and TMP-SMX (8/40) vs chloramphenicol (100), doxycycline (4), and TMP-SMX (8/40)10-1413627 vs 3418.5 vs 47
419 Ceftazidime (120) vs amoxicillin-clavulanate (120/40)At least 7379106 vs 10539 vs 5147 vs 47
383 Ceftazidime (120) vs imipenem (50)At least 10296106 vs 10841 vs 2038 vs 36
423 Ceftazidime (25) and co-trimoxazole (8/40) vs cefoperazone-sulbactam (100) and co-trimoxazole (8/40)8420 vs 2021 vs 16
90 Ceftazidime (100) and TMP-SMX (8/40) vs Cefoperazone-sulbactam (25/25)1421951 vs 5114 vs 18
W. Chierakul et al., unpublished dataCeftazidime (120) vs ceftazidime (120) and TMP-SMX (10/50)10 days449118 vs 123No significant difference